Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 515.77M | 550.42M | 586.87M | 512.92M | 424.07M |
Gross Profit | 189.15M | 190.86M | 210.54M | 184.62M | 139.06M |
EBITDA | 108.17M | 107.19M | 113.22M | -32.58M | 74.99M |
Net Income | 58.11M | 60.53M | 59.58M | -41.87M | 34.69M |
Balance Sheet | |||||
Total Assets | 766.11M | 741.17M | 748.49M | 664.46M | 626.05M |
Cash, Cash Equivalents and Short-Term Investments | 94.33M | 163.88M | 156.91M | 141.47M | 91.77M |
Total Debt | 117.09M | 96.86M | 109.36M | 74.75M | 81.06M |
Total Liabilities | 235.26M | 214.34M | 242.26M | 200.88M | 202.37M |
Stockholders Equity | 530.85M | 526.82M | 506.22M | 463.58M | 423.68M |
Cash Flow | |||||
Free Cash Flow | 80.64M | 74.07M | 106.86M | 70.50M | 61.92M |
Operating Cash Flow | 99.29M | 88.81M | 121.20M | 86.14M | 76.78M |
Investing Cash Flow | -140.56M | -18.10M | -111.19M | -15.90M | -23.17M |
Financing Cash Flow | -27.93M | -65.40M | 4.34M | -20.71M | -61.33M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $4.82B | 52.33 | 5.89% | ― | 14.24% | 424.78% | |
77 Outperform | $2.18B | 34.09 | 11.44% | ― | 2.46% | 572.04% | |
74 Outperform | $1.22B | 19.55 | 11.96% | 0.38% | 1.16% | 19.81% | |
69 Neutral | $1.42B | 37.84 | 3.49% | 1.71% | -5.95% | -43.46% | |
68 Neutral | ¥241.22B | 15.24 | 6.62% | 2.44% | 9.24% | 1.58% | |
57 Neutral | $1.36B | 72.21 | -5.25% | ― | -7.61% | -212.91% | |
42 Neutral | $348.08M | ― | -0.38% | 0.92% | 8.33% | 99.75% |
CTS Corporation presented an investor presentation for the fiscal year ending December 31, 2025, highlighting its strategic focus on growth and diversification across various end markets. The company aims to deliver 10% organic and inorganic growth by leveraging its deep custom engineered capabilities, strong customer relationships, and a robust new product pipeline. CTS is positioned to capitalize on megatrends such as automation, healthcare innovation, and electrification, supported by a strong balance sheet and cash flow to pursue strategic mergers and acquisitions. The company’s diversified end markets, including industrial, medical, and aerospace and defense, show promising growth prospects with significant revenue contributions and market opportunities.
The most recent analyst rating on (CTS) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on CTS stock, see the CTS Stock Forecast page.
On July 24, 2025, CTS Corporation announced its financial results for the second quarter of 2025, reporting a 4% year-over-year increase in sales to $135 million. The company achieved a net income of $19 million, up from $15 million in the same quarter of 2024, and an adjusted EBITDA margin of 23.0%. Despite a 6% decrease in sales to the transportation market, sales to diversified end markets grew by 13%. CTS maintains its 2025 guidance for sales and adjusted diluted EPS, indicating a focus on strategic diversification through organic growth and acquisitions.
The most recent analyst rating on (CTS) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on CTS stock, see the CTS Stock Forecast page.
On July 1, 2025, CTS Corporation appointed Mark Pacioni as Chief Legal & Administrative Officer and Corporate Secretary. Mr. Pacioni brings over 30 years of legal experience, having previously served in senior roles at CareerBuilder, LLC, and its successor, as well as at Knowles Corp., Molex, Inc., and Boeing. His extensive background is expected to contribute significantly to CTS’s global strategy and business diversification efforts.
The most recent analyst rating on (CTS) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on CTS stock, see the CTS Stock Forecast page.